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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanBackground: The aim of this study was to elucidate risk factors for mortality after developing
sepsis in pediatric patients with hematologic and malignant disorders.
Methods: A total of 90 patients (43 boys, 47 girls) with various hematologic and malignant dis-
eases who experienced sepsis between June 2006 and March 2014 were enrolled. Clinical and
laboratory features of 134 episodes of sepsis observed in the 90 patients were compared be-
tween those with and without sepsis-related death which was defined as death within 14 days
after sepsis.
Results: Age at hospitalization, sex, and type of underlying disease did not differ between pa-
tients with and without sepsis-related death. Sepsis episode-based univariate analysis identi-
fied patients with a history of relapse or in a refractory state of underlying disease (p< 0.01),
those with high C-reactive protein concentrations (50 mg/L) at the beginning of fever
(p< 0.01), those who had undergone hematopoietic stem cell transplantation (p< 0.01),
and those who were forced to change initial antibiotics (p Z 0.02) because of being at high
risk of sepsis-related death. The former two factors were further confirmed by multivariate
analysis. More than half (52.9%) the isolates from sepsis-related death were Gram-positive
cocci resistant to b-lactam antibiotics, but susceptible to vancomycin.
Conclusion: It was found that a history of relapse, a refractory state of underlying disease, and
high C-reactive protein concentrations at the beginning of fever were significant risk factorsof Pediatrics, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo 003-0006, Japan.
ail.com (H. Sano).
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malignant diseases, Journal of Microfor mortality after developing sepsis. Survival rate of patients with risk factors raised in this
study might be improved by early introduction of vancomycin.
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Recent advances in chemotherapy and hematopoietic stem
cell transplantation (HSCT) have improved the survival rate
of pediatric patients with hematologic and malignant dis-
orders and bone marrow failure syndrome. Nonetheless,
the accompanying intensification of therapy, such as
multidrug chemotherapy and HSCT, has led to an increased
incidence of severe infection including sepsis. Sepsis is still
a major cause of morbidity and mortality in patients with
hematologic and malignant diseases, although various
antibacterial/antifungal treatments have been developed.
Limited data characterizing mortality after developing
sepsis have been reported for children and adolescents.1e4
New medical treatment strategies might be produced by
the identification of risk profiles, and may lead to better
survival. Thus, the aim of this study was to elucidate the
risk factors for mortality after developing sepsis in children
and adolescents with hematologic and malignant disorders
receiving chemotherapy, immunosuppressive therapy, and
HSCT.Methods
Patients
A total of 90 consecutive patients (43 boys, 47 girls) at
Sapporo Hokuyu Hospital, Sapporo, Japan with various he-
matologic malignancies, aplastic anemia, or solid tumors
who experienced sepsis following chemotherapy, immuno-
suppressive therapy, and HSCT between June 2006 and
March 2014 were enrolled in this study. The age at admis-
sion ranged from 4 months to 24 years (median, 8 years).
Forty-three patients had acute lymphoblastic leukemia, 25
had acute myeloid leukemia, four had neuroblastoma,
three had aplastic anemia, three had myelodysplastic syn-
drome (including juvenile myelomonocytic leukemia), two
had non-Hodgkin lymphoma, two had hepatoblastoma, two
had rhabdomyosarcoma, one had congenital dysery-
thropoietic anemia, and five had other malignant diseases
including retinoblastoma, alveolar soft part sarcoma, der-
matofibrosarcoma protuberans, epithelioid sarcoma, and
pancreatic neuroendocrine tumor. During the study period,
22 patients received HSCT: 21 of them received allogeneic
HSCT and one received autologous HSCT. A total of 134
episodes of sepsis were observed in the 90 patients during
the study period.
Informed consent was obtained from the patients and/or
their parents, according to guidelines based on the tenets
of the revised Helsinki protocol. The institutional review
board of Sapporo Hokuyu Hospital approved this project.no H, et al., Risk factors for seps
biology, Immunology and InfectioDefinitions of sepsis, fever, neutropenia, and
sepsis-related death
Sepsis is defined as systemic inflammatory response syn-
drome in the presence of suspected or proven infection and
organ dysfunction according to international consensus
guideline5,6; however, in this study, we dealt with the cases
in which bacterial/fungal pathogens were isolated from
blood of patients. When bacteria that typically colonize the
skin, such as coagulase-negative staphylococci, cor-
ynebacteriae other than Corynebacterium jeikeium, and
other skin contaminants, were isolated, at least two
consecutive blood cultures were analyzed to confirm the
pathogenicity of the isolates. Blood cultureswere performed
in response to a sign of infection, which was typically fever.
Fever was defined in this study as an axillary temperature of
37.5C on two occasions at least 1 hour apart or a single
axillary temperature >38.0C. Neutropenia was defined as
an absolute neutrophil count of <0.5  109/L.
When evaluating the prognosis of sepsis, it is difficult to
distinguish strictly whether patients died from sepsis or not.
The prognosis of sepsis is often evaluated by the death rate at
28 days after sepsis development in such as an intensive care
area7; however,whenanevaluation period becomes longer in
patients with hematological and malignant disease, involve-
mentof factors ofdeathother than sepsis (for example,death
due to underlying malignant disease) might increase. There-
fore, we decided to analyze prognostic factors of sepsis using
the concept of sepsis-related death, which was defined as
death within 14 days after developing sepsis.
Analytic procedures
To evaluate the background of the enrolled patients, sex,
age at hospitalization, and type of underlying disease were
compared between patients (a total of 90 patients) with
and without sepsis-related death.
Meanwhile, to evaluate the risk factors of sepsis-related
death, a total of 134 sepsis episodes observed in the 90
patients were analyzed between patients with and without
sepsis-related death for factors including laboratory data at
the beginning of fever, condition of underlying disease
(history of relapse or refractory state), insertion of a cen-
tral venous catheter, history of HSCT, changes of initial
antibiotics due to prolonged or recurrent fever, and type of
isolated pathogen. Data were analyzed as of May 1, 2014.
Infection prophylaxis
Trimethoprimesulfamethoxazole was prescribed to all pa-
tients for the prevention of Pneumocystis jiroveciiis-related death in children and adolescents with hematologic and
n (2015), http://dx.doi.org/10.1016/j.jmii.2015.04.002
Risk factors for sepsis-related death 3
+ MODELpneumonia. Prophylactic administration of oral vor-
iconazole at 5e10 mg/kg/d was used for patients with
acute myeloid leukemia, whereas oral fluconazole at
10 mg/kg/d was used for all other patients. For stem cell
transplantation patients, intravenous micafungin at 1 mg/
kg/d was administered from the beginning of the condi-
tioning regimen until neutrophil recovery, followed by the
oral administration of fluconazole at 10 mg/kg/d from the
time of neutrophil recovery until the date of discharge.
Prophylactic administration of antibacterial agents was not
routinely performed.
Identification and initial treatment of sepsis
All eligible patients were hospitalized. When patients
developed fever during neutropenia, the following labora-
tory tests were performed: complete blood cell count,
peripheral blood smear, quantitative C-reactive protein
(CRP), liver and renal function, urinalysis, and blood cul-
tures from specimens obtained via peripheral venous
puncture and/or a central venous catheter, if in place.
Antimicrobial therapy was begun as soon as possible
without waiting for the result of blood culture. The initial
antibacterial drugs at the onset of fever were as follows:
ceftazidime plus piperacillin/tazobactum (PIPC/TAZ) or
sulbactam/ampicillin plus aztreonam from June 1, 2004, to
March 31, 2006;8 ceftazidime plus PIPC/TAZ or cefozopran
monotherapy from April 1, 2006, to March 31, 2008;9
cefozopran monotherapy or cefepime monotherapy from
April 1, 2008, to March 31, 2010;10 PIPC/TAZ monotherapy
or cefepime monotherapy from April 1, 2010, to March 31,
2012;11 and PIPC/TAZ monotherapy or meropenem mono-
therapy from April 1, 2012, to March 31, 2014 (data not
shown).
Initial antimicrobials were continued when a case of
fever was alleviated following initiation of antimicrobials.
In a case of fever continuing following initiation of anti-
microbials, or once resolved fever and infectious signs
subsequently recurred in spite of the continuation of the
same antimicrobial therapy, the laboratory test including
blood culture was reexamined and the antimicrobial ther-
apy was changed to other antibacterial drugs or antifungal
drugs (changes of initial antimicrobial ). When a bacterial
infection was suspected in a case without neutropenia, the
laboratory test including blood culture was done before the
initiation of antimicrobial therapy.
Statistical analysis
A c2 test or ManneWhitney U test was used to compare
patients with or without sepsis-related death. Risk factors
for sepsis-related death were evaluated by univariate and
multivariate analyses using the Cox regression model. A
multivariate model was constructed by the forward step-
wise method using threshold p values of 0.05 for removal or
additions to the model. Values of p< 0.05 were considered
significant. Measures of association are expressed as hazard
ratios with a 95% confidence interval. The cut-off point for
CRP level was determined based on the value of Youden
Index by constructing a receivereoperating characteristic
curve. All statistical analyses were performed using EZRPlease cite this article in press as: Sano H, et al., Risk factors for seps
malignant diseases, Journal of Microbiology, Immunology and Infectio(Saitama Medical Center, Jichi Medical University, Shi-
motsuke, Japan), which is a graphical user interface for R
(The R Foundation for Statistical Computing, Vienna,
Austria). More precisely, it is a modified version of the R
commander designed to add statistical functions frequently
used in biostatistics.12
Results
Isolated bacteria/fungi
A total of 136 pathogens were isolated at 134 episodes of
sepsis which occurred in 90 patients (Table 1). Two organ-
isms were detected at the same time in 2 patients (Enter-
obacter cloacae and aestreptococcus were isolated in one
patient, whereas Enterococcus sp. and Staphylococcus
epidermidis were isolated in the other patient). Gram-
positive cocci were the most common pathogens among
isolated organisms, constituting 72.8% of the total, fol-
lowed by Gram-negative bacilli (18.4%), Gram-positive
bacilli (7.4%), and fungi (Candida species, 1.5%). The most
common pathogen among isolated organisms in patients
with sepsis-related death was Gram-positive cocci (82.4%),
followed by Gram-negative bacilli (17.6%). There were no
patients with sepsis-related death caused by Gram-positive
bacilli and fungi.
Gram-positive cocci were the most common pathogen
among isolated organisms regardless of underlying diseases.
The distribution of pathogen did not differ significantly in
each underlying disease. Of 17 isolates from sepsis-related
death, nine (52.9%) were Gram-positive cocci (Staphylo-
coccus epidermidis, n Z 6; Enterococcus faecium, n Z 1;
Enterococcus sp., n Z 2] resistant to belactam antibiotics
(penicillin derivatives, cephalosporins, monobactams, and
carbapenems), but susceptible to vancomycin. Of seven
patients who died from sepsis of S. epidermidis, five pa-
tients (71.4%) had history of relapse or were in refractory
state of underlying disease.
Risk factors for sepsis-related death
Age at hospitalization, sex, and type of original disease did
not differ between patients with and without sepsis-related
death (Table 2).
Meanwhile, as a result of the risk factor analysis of
sepsis-related death (Table 3), the frequency of cases with
a history of relapse or in a refractory state of underlying
disease (nonremission) was significantly higher in those
with sepsis-related death than in those without (69.2% vs.
22.6%, p Z 0.0011; the studied cases were 128 cases with
malignant disease, excluding 4 cases with aplastic anemia
and 2 cases with congenital dyserythropoietic anemia). In
addition, the frequency of cases that had experienced
HSCT was higher in those with sepsis-related death than in
those without (60.0% vs. 16.0%, pZ 0.0015). The frequency
of cases with changes of initial antimicrobials was also
higher in those with sepsis-related death than in those
without (40.0% vs. 14.3%, p Z 0.0233). In the laboratory
data, values of CRP at the beginning of a sepsis episode
were significantly higher in those with sepsis-related death
than in those without (85 mg/L vs. 13.9 mg/L, pZ 0.0005).is-related death in children and adolescents with hematologic and
n (2015), http://dx.doi.org/10.1016/j.jmii.2015.04.002
Table 1 Isolated pathogens on blood culture.
Isolate Total
numbera
Number of
episodes with
sepsis-related
deathb
Gram-positive cocci 99 (72.6) 14 (82.4)
Staphylococcus aureus 9 (6.6) 1 (5.9)
Staphylococcus epidermidis 44 (32.4) 7 (41.2)
Staphylococcus capitis 1 (0.7) 0
a-Streptococcus spp. 18 (13.2) 1 (5.9)
Streptococcus viridans 6 (4.4) 0
Streptococcus mitis 2 (1.5) 0
Streptococcus oralis 5 (3.7) 0
Streptococcus pneumoniae 1 (0.7) 1 (5.9)
Streptococcus sanguis 2 (1.5) 0
Streptococcus pyogenes 1 (0.7) 0
Streptococcus intermedius 1 (0.7) 0
Micrococcus species 2 (1.5) 0
Enterococcus faecium 2 (1.5) 1 (5.9)
Enterococcus faecalis 2 (1.5) 1 (5.9)
Enterococcus species 3 (2.2) 2 (11.8)
Gram-positive bacilli 10 (7.4) 0
Bacillus subtilis 4 (2.9) 0
Bacillus cereus 2 (1.5) 0
Bacillus species 4 (2.9) 0
Gram-negative bacilli 25 (18.4) 3 (17.6)
Escherichia coli 7 (5.1) 1 (5.9)
Enterobacter cloacae 5 (3.7) 1 (5.9)
Klebsiella pneumoniae 4 (2.9) 0
Pantoea agglomerans 3 (2.2) 0
Pseudomonas aeruginosa 3 (2.2) 1 (5.9)
Pseudomonas stutzeri 1 (0.7) 0
Pseudomonas species 1 (0.7) 0
Capnocytophaga species 1 (0.7) 0
Fungi 2 (1.5) 0
Candida spp. 2 (1.5) 0
Total 136 17
a A total of 136 bacteria/fungi in 134 episodes were isolated (2
organisms were isolated at the same time in 2 patients).
b A total of 17 bacteria in 15 episodes with sepsis-related
death were isolated (2 organisms were isolated at the same
time in 2 patients).
Data are presented as n (%).
Table 2 Background of the patients who experienced
sepsis with and without sepsis-related death (n Z 90).
Patients with
sepsis-related
death (n Z 15)
Patients without
sepsis-related
death (n Z 75)
p
Age (y) 8 (0e18) 6 (0e24) 0.6565
Sex > 0.99
Male 7 (46.7) 36 (48.0)
Female 8 (53.3) 39 (52.0)
Disease 0.0994
ALL 6 (40.0) 37 (49.3) 0.5796
AML 2 (13.3) 23 (30.7) 0.2192
MDS þ JMML 2 (13.3) 1 (1.3) 0.7091
Solid tumor 3 (20.0) 12 (16.0) 0.7097
AA þ CDA 2 (13.3) 2 (2.7) 0.1279
Data are presented as n (%) or median (range).
AA Z aplastic anemia; ALL Z acute lymphoblastic leukemia;
AML Z acute myeloid leukemia; CDA Z congenital dysery-
thropoietic anemia; JMML Z juvenile myelomonocytic leuke-
mia; MDS Z myelodysplastic syndrome.
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was determined by constructing a receivereoperating
characteristic curve, with 78.8% sensitivity and 66.7%
specificity) and a history of relapse or a refractory state of
underlying disease in sepsis-related death was further
confirmed by multivariate analysis (Table 4). Other labo-
ratory data, including white blood cell count, neutrophil
count at the beginning of fever in a sepsis episode, pres-
ence of central venous catheter, and type of isolated
pathogen, did not differ between the two groups.
Discussion
Infectious diseases have been major causes of morbidity
and mortality in immunocompromized patients with can-
cer. Approximately 10e30% of febrile neutropenic patientsPlease cite this article in press as: Sano H, et al., Risk factors for seps
malignant diseases, Journal of Microbiology, Immunology and Infectiowith cancer are reported to be complicated with sepsis at
presentation.13,14 Although advances in supportive care
have permitted patients to recover successfully from the
impact of cytotoxic cancer chemotherapy, HSCT, radiation
therapy, aggressive surgical intervention, and intense
immunosuppression, sepsis is still a major issue leading to
unexpected death. However, there are limited data con-
cerning morbidity and mortality after developing sepsis in
children and adolescents.1e4,15e17 To improve the survival
of patients with sepsis, understanding the risk profile of
death due to sepsis is important in the application of
medical interventions for high-risk patients. Thus, we
aimed to elucidate the risk factors for mortality after
developing sepsis in children and adolescents with hema-
tologic and malignant disorders receiving chemotherapy,
immunosuppressive therapy, and/or HSCT.
In this study, high CRP concentrations (50 mg/L) at the
beginning of a sepsis episode and a history of relapse or a
refractory state of underlying disease were identified as
risk factors of sepsis-related death by multivariate analysis.
A high CRP concentration is acknowledged as an indi-
cator of significant systemic bacterial/fungal infection.
Santolaya et al15 reported that a CRP level of 90 mg/L and
the presence of hypotension were indicators of invasive
systemic bacterial infection; however, the cut-off point for
CRP level (50 mg/L) identified in the present analysis as a
risk factor for sepsis-related death was much lower than in
the above-mentioned report. Critical cut-off threshold CRP
concentration varies widely because it is primarily deter-
mined by the sensitivity of the test.18 CRP can be elevated
from infectious and noninfectious causes such as tissue
inflammation or necrosis, or advanced stage of malignant
disease19; therefore, specificity of CRP tends to be low. The
discrepancy in cut-off CRP concentration between our
study and past reports might be simply due to differences in
timing for checking CRP. CRP, an acute phase protein,
usually elevates within 12e24 hours after the onset of
fever, however, it often does not rise at the beginning of
fever even in the case of true bacterial infections. Unlikeis-related death in children and adolescents with hematologic and
n (2015), http://dx.doi.org/10.1016/j.jmii.2015.04.002
Table 3 Risk factors for sepsis-related death: sepsis episode-based, univariate analysis (n Z 134).
Cases with sepsis-related
death (n Z 15)
Cases without sepsis-related
death (n Z 119)
p
Laboratory data at the beginning of sepsis episode
WBC ( 106/L) 200 (10e115,180) 270 (10e13,900) 0.6578
Neutrophils ( 106/L) 17 (0e30,422) 37 (0e11,049) 0.8060
CRP (mg/L) 85 (4.2e376.9) 13.9 (0.5e205.1) 0.0005
History of relapse/refractory statea 9 (69.2) 26 (22.6) 0.0011
Presence of CVC 12 (80.0) 57 (52.1) 0.0536
History of HSCT 9 (60.0) 19 (16.0) 0.0015
Changes of initial antibiotics 6 (40.0) 17 (14.3) 0.0233
Types of pathogenb 0.7877
Gram-positive cocci 14 (82.4) 85 (71.4) 0.5603
Coagulase-negative staphylococci 7 (41.2) 45 (37.8) 0.7951
Gram-positive bacilli 0 10 (8.8) 0.3622
Gram-negative bacilli 3 (17.6) 22 (18.5) > 0.99
Fungi (Candida) 0 2 (1.8) > 0.99
a Excluding those with nonmalignant disease (4 cases with aplastic anemia and 2 cases with congenital dyserythropoietic anemia).
b Two organisms were isolated at the same time in two patients (both were included in cases with sepsis-related death); thus, the total
number of primary causative organisms was defined as 136.
Data are presented as n (%) or median (range).
CRP Z C-reactive protein; CVC Z central venous catheter; HSCT Z hematopoietic stem cell transplantation; WBC Z white blood cell
count.
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fever, others employed CRP concentrations taken at
different timing; CRP concentration on the next day or the
day after next of the fever,18 peak CRP concentration
throughout the whole course of fever,16 peak CRP concen-
tration within 48 hours after the onset of fever,4 and in-
crease rate of CRP from 24 hours to 48 hours after the onset
of fever.20
In cases in which CRP is already elevated at the begin-
ning of fever, a stronger inflammatory reaction might be
induced compared with cases with a lower CRP concen-
tration. Moreover, the tissue damage induced by cytokine
storm might become obvious in such cases. Meanwhile,
cases in which CRP is already elevated at the beginning of
fever included more cases with a history of relapse or re-
fractory underlying disease than those with low CRP con-
centration (41.2% vs. 22.3%, respectively, p Z 0.0441).
Patients with elevated CRP possibly due to poor-controlled
underlying disease might progressively deteriorate in gen-
eral condition as a result of subsequent septic events,Table 4 Multivariate analysis of risk factors for sepsis-
related death extracted by univariate analysis.
Hazard
ratio
p 95% CI
CRP  50 mg/La 4.750 0.0269 1.20e18.90
History of relapse/
refractory state
4.170 0.0464 1.02e17.00
History of HSCT 2.890 0.1600 0.66e12.70
Changes of initial antibiotics 1.640 0.5020 0.39e6.98
a The cut-off point for CRP level was determined by con-
structing a receiver operator curve.
CI Z confidence interval; CRP Z C-reactive protein;
HSCT Z hematopoietic stem cell transplantation.
Please cite this article in press as: Sano H, et al., Risk factors for seps
malignant diseases, Journal of Microbiology, Immunology and Infectioleading to death, which could explain the strong association
between the high value of CRP and sepsis-related death.
Patients with a history of relapse or in a refractory state
of underlying disease might receive repeated and intensive
chemotherapy, causing severe bone marrow suppression
and/or organ dysfunction, such as liver and/or renal
dysfunction. Prolonged neutropenia21 and organ dysfunc-
tion22 have been reported to be prognostic factors of severe
sepsis. Organ dysfunction might get worse owing to dete-
riorating infection during prolonged neutropenia, leading to
death. To the best of our knowledge, there have been no
reports identifying a history of relapse or a refractory state
as a prognostic factor of sepsis.
The mortality rate of sepsis in this study was 11.2% (15/
134), which was higher than those of previous reports
(1e4%).1e4,15 This discrepancy might be due to differences
in the studied patients. Although cases with a history of
relapse or in a refractory state, which were among the
potent risk factors for sepsis-related death as defined in
this study, were not included in the studies described in
previous reports,1e4,15 such cases constituted 26.1% of our
analyzed patients. The mortality rate of patients with
sepsis excluding those with a history of relapse or in a re-
fractory state in this study was almost the same as in pre-
vious studies1e4,15; thus, the higher mortality rate in our
study could be explained simply by the higher rate of cases
with a history of relapse or in a refractory state in the study
population. In other research that included many cases
with a history of relapse or in a refractory state like in our
study, a higher mortality rate (23.7%) was reported.23
Among isolated pathogens of sepsis in this study, Gram-
positive cocci were the most common, regardless of the
underlying disease. Until the late 1970s, aerobic Gram-
negative bacilli (especially Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa) were the most
frequently isolated pathogens. Subsequently, the patternis-related death in children and adolescents with hematologic and
n (2015), http://dx.doi.org/10.1016/j.jmii.2015.04.002
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are now isolated more often than Gram-negative bacteria
in most oncology institutes.13,14 The main reasons for this
shift to Gram-positive isolates could be the recent increase
in the use of indwelling central venous catheters and fluo-
roquinolone prophylaxis, and the recent prevalence of oral
mucositis induced by intensive chemotherapy. Although the
attributable morbidity and mortality rates associated with
infections due to coagulase-negative staphylococci and
enterococci have been reported to be lower than those
caused by Gram-negative bacilli,24 sepsis caused by a-he-
molytic streptococci, most commonly S., may cause sudden
onset of hypotension, with progression in approximately
one-quarter of cases to a syndrome that can include shock,
respiratory failure due to adult respiratory distress syn-
drome, acute renal failure, and neurologic manifesta-
tions.25,26 Fortunately, no fatal cases due to Streptococcus
mitis were observed in this study period; however, special
caution is now warranted for its association with sepsis.
Although infection due to coagulase-negative staphylo-
cocci is generally treatable and known to cause less mor-
tality,24 S. epidermidis was the leading cause of sepsis-
related death in this study. Of seven patients who died
from sepsis of S. epidermidis, five (71.4%) had history of
relapse or were in refractory state of underlying disease.
These patients might have organ dysfunctions, and pro-
longed myelosuppression potentially due to repeated and
intensive chemotherapy; therefore, even the mild path-
ogen, S. epidermidis, could be a cause of unexpected
death. Meanwhile, more than half (52.9%) the isolates from
sepsis-related death were Gram-positive cocci resistant to
b-lactam antibiotics, but susceptible to vancomycin. From
this point of view, survival rate of the patients with risk
factors raised in this study could be improved by intro-
ducing vancomycin from an early phase of fever.
We had worked on prospective, randomized studies to
compare the effectiveness of various antimicrobial regi-
mens against sepsis in the patients of this study period8e11
and found that there was no difference in the mortality
rate for each regimen (data not shown). Thus, it seems
feasible to say that findings of this research are not influ-
enced by difference of the first line antibiotics.
In conclusion, we identified a history of relapse or a
refractory state of underlying disease, as well as a high CRP
concentration (50 mg/L) at the beginning of fever, as
significant risk factors of mortality after developing sepsis
in children and adolescents with hematologic and malig-
nant diseases. Early introduction of vancomycin to the pa-
tients with risk factors raised in this study might improve
their survival rate.Conflicts of interest
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